A novel approach to immunotherapy developed by NCI researchers has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. The findings were published in Nature Medicine.
The NCI-MATCH precision medicine clinical trial has reached a milestone with the release of results from several study treatment arms. Findings from three arms were released at the 2018 ASCO annual meeting, adding to findings from one arm released in 2017.
Findings from the TAILORx clinical trial show chemotherapy does not benefit most women with early breast cancer. The new data, released at the 2018 ASCO annual meeting, will help inform treatment decisions for many women with early-stage breast cancer.
A fact sheet that provides an overview of how the immune system functions and describes the actions of biological therapies, such as monoclonal antibodies, cytokines, therapeutic vaccines, the bacterium bacillus Calmet-Guérin, cancer-killing viruses, gene therapy, and adoptive T-cell transfer.